Clearmind Secures Japanese Patent for 3-MMC-Based Neurological Disorder Treatment

  • Clearmind's Japanese patent application covers 3-MMC-based treatment for dyskinesia, a neurological movement disorder.
  • The patent includes combinations of 3-MMC with Palmitoylethanolamide (PEA), an anti-inflammatory and neuroprotective compound.
  • This development is part of Clearmind's ongoing collaboration with NeuroThera Labs Inc.
  • Clearmind currently holds 19 patent families, including 32 granted patents.
  • The patent publication occurred on October 8, 2026.

Clearmind's patent publication in Japan underscores its strategy to build a robust intellectual property portfolio around its neuroplastogen-derived therapeutics. This move aligns with broader industry trends of leveraging psychedelic-derived compounds for treating underserved neurological conditions. The collaboration with NeuroThera Labs further solidifies Clearmind's position in the biopharmaceutical sector, particularly in the development of non-hallucinogenic treatments for conditions like dyskinesia.

IP Expansion
How Clearmind's global IP position will strengthen its market advantage in treating neurological disorders.
Clinical Progress
The pace at which Clearmind advances its 3-MMC-based treatments through clinical trials.
Partnership Dynamics
Whether the collaboration with NeuroThera Labs will yield additional therapeutic breakthroughs.